CV Sciences, Inc. reported revenue of $3.6 million for the second quarter of 2025, consistent with the first quarter of 2025, but a decrease from $4.0 million in the second quarter of 2024. Despite the revenue change, the company achieved significant financial milestones.
The company recognized a gross margin of 50.9% for the second quarter of 2025, marking its highest gross margin since the third quarter of 2019. This represents a notable increase from 47.0% in Q2 2024 and 46.0% in Q1 2025, driven by lower freight, inventory losses, and product mix.
Crucially, CV Sciences reported positive Adjusted EBITDA of $0.1 million for the second quarter of 2025, its first positive Adjusted EBITDA since the second quarter of 2019. This achievement underscores the effectiveness of the company's cost-cutting and efficiency initiatives, signaling a significant turn towards financial health.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.